The TRANSVAC Services are providing researchers with free access to:

• Adjuvant formulation
• Animal models
• Standards
• Global analyses (e.g. microarrays & deep sequencing)

The Services are at the core of the TRANSVAC project. Read the detailed description of Services available.

In order to support and accelerate vaccine development in Europe, TRANSVAC is providing a transnational vaccine development platform which may be accessed free of charge by innovative European vaccine Research and Development (R&D) groups. Through a peer-reviewed competitive process (see: OPEN CALL), European groups working in vaccine development may apply to benefit from the expertise, reagents, and facilities of TRANSVAC consortium. Only European User groups - from European Union (EU) Members States or Associated States - can apply for the free Services, and only to TRANSVAC Service infrastructures outside their own country. For scientists based in countries outside the EU Member States or its Associated States, access is subject to a range of charges according to the Service in question. TRANSVAC’s vaccine development Services are not linked to any particular type of disease.

The permanent call for free Services in vaccine development will remain open for the duration of the project (until September 2013), or until all of the Services have been exhausted. There are several cut-off dates for evaluation of proposals foreseen.  Applications will be reviewed by the TRANSVAC Scientific Advisory Committee and User Selection Panel. Full information on eligibility criteria and on the application and selection process can be found under OPEN CALL. 

Detailed information on the individual Services can be found under Services available.